secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001387131-22-002256
Event type: leadership
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals director Dr. Daniel Goodman will not stand for reelection at 2022 annual meeting
--------------------------------------------------------------------------------

- Dr. Daniel Goodman notified Tonix on Feb 16, 2022, of his decision not to stand for reelection.
- He will continue as director and retain committee memberships through the 2022 Annual Meeting.
- No replacement director has been announced; the 2022 Annual Meeting date is not specified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713122002256/0001387131-22-002256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713122002256/tnxp-8k_021622.htm
  HTML page:      https://secwatch.observer/filing/0001387131-22-002256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer